BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38295753)

  • 1. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.
    Li F; Zhang H; Huang Y; Li D; Zheng Z; Xie K; Cao C; Wang Q; Zhao X; Huang Z; Chen S; Chen H; Fan Q; Deng F; Hou L; Deng X; Tan W
    Drug Resist Updat; 2024 Mar; 73():101059. PubMed ID: 38295753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Xu C; Zhou J; Zhang X; Kang X; Liu S; Song M; Chang C; Lin Y; Wang Y
    Cell Mol Biol Lett; 2024 Feb; 29(1):28. PubMed ID: 38395751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway.
    Feng D; Lv J; Li K; Cao Q; Han J; Yu H; Cheng Y; Zhuang J; Cai L; Yang H; Yang X; Lu Q
    Cell Biol Toxicol; 2023 Oct; 39(5):1-18. PubMed ID: 35567596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
    Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer.
    Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
    Oncol Rep; 2016 Mar; 35(3):1549-56. PubMed ID: 26717965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.
    Yang C; Ou Y; Zhou Q; Liang Y; Li W; Chen Y; Chen W; Wu S; Chen Y; Dai X; Chen X; Chen T; Jin S; Liu Y; Zhang L; Liu S; Hu Y; Zou L; Mao S; Jiang H
    Cell Death Dis; 2023 Aug; 14(8):525. PubMed ID: 37582769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway.
    Li C; Su H; Ruan C; Li X
    Folia Histochem Cytobiol; 2021; 59(1):40-48. PubMed ID: 33577073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.
    Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
    Int J Oncol; 2016 Jan; 48(1):225-34. PubMed ID: 26647959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.
    Li W; Zhou C; Yu L; Hou Z; Liu H; Kong L; Xu Y; He J; Lan J; Ou Q; Fang Y; Lu Z; Wu X; Pan Z; Peng J; Lin J
    Autophagy; 2024 Jan; 20(1):114-130. PubMed ID: 37615625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
    Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
    Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance.
    Wei W; Liu K; Huang X; Tian S; Wang H; Zhang C; Ye J; Dong Y; An Z; Ma X; Wang B; Huang Y; Zhang X
    J Exp Clin Cancer Res; 2024 Jan; 43(1):2. PubMed ID: 38163881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer.
    Xie B; Lin J; Chen X; Zhou X; Zhang Y; Fan M; Xiang J; He N; Hu Z; Wang F
    Mol Cancer; 2023 Sep; 22(1):151. PubMed ID: 37684641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
    J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMI1 activates P-glycoprotein via transcription repression of
    Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
    Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
    Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
    Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
    Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
    Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.